<DOC>
	<DOCNO>NCT01000870</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety MNI-513 positron emission tomography ( PET ) detection/exclusion cerebral amyloid beta patient Alzheimer 's disease compare healthy volunteer .</brief_summary>
	<brief_title>Safety Efficacy Positron Emission Tomography Imaging With MNI-513</brief_title>
	<detailed_description>To determine diagnostic efficacy MNI-513 PET scan differentiate patient probable AD HVs basis neocortical tracer bind pattern , PET scan visually assess nuclear physician experience field neuro-imaging . PET scan finding classify either abnormal ( i.e. , significant neocortical uptake predefined region ) normal ( i.e . significant neocortical uptake predefined region ) . The nuclear physician unaware clinical diagnosis .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : ALZHEIMER &amp; HEALTHY VOLUNTEERS 1. man woman ≥ 55 age , whereby female must without childbearing potential ( confirm either : age ≥ 60 ; history surgical sterilization hysterectomy , last spontaneous bleed least 2 year prior study start ) 2. least 6 year education 3. able provide inform consent assent , exhibit adequate visual , auditory communication capability enable compliance study procedure . This include perform psychometric test able lie flat PET scanner 4. posse general health permit adequate compliance study procedure ascertain detailed review medical history , laboratory physical examination finding , must perform within 28 day prior administration IMP 5. subject , subject caregiver ( probable AD patient ) compliant high probability complete study opinion investigator 6. informed consent sign date ( time ) subject and/or subject 's caregiver ( probable AD patient ) INCLUSION CRITERIA : HEALTHY VOLUNTEERS ONLY 1. evidence cognitive impairment indicate clinical dementia rating ( CDR , [ Hughes et al . 1993 ] ) score 0 ( zero ) score ≥ 28 MiniMental Status Examination ( MMSE , [ Folstein et al . 1975 ] ) 2. CERAD neuropsychological test battery [ Welsh et al . 1994 ] z score ≥ ( 1.00 ) subtest ( except MMSE cover criterion 1 ) 3. MRI brain scan judge `` normal ( age appropriate ) '' include ARWMC scale [ Wahlund et al . 2001 ] score support lack cerebrovascular disease ( e.g. , white matter lesion score 0 1 2 basal ganglion score 0 1 ) Scheltens scale [ Scheltens et al . 1992 ] verify lack cerebral atrophy ( e.g . bilateral temporal lobe atrophy visual score 0 1 ) INCLUSION CRITERIA : PROBABLE ALZHEIMER DISEASE ONLY 1. present positive assessment dementia Alzheimer 's type accordance DSMIVTR probable AD accord NINCDSADRDA criterion fulfil none exclusion criterion either ( see Appendix 1,2 ) 2. fulfill ICC criterion probable DLB ( Appendix 3 ) , NINDSAIREN probable Vascular dementia ( Appendix 5 ) , Neary [ Neary et al . 1998 ] criterion FTD ( Appendix 4 ) 3. CDR [ Hughes et al . 1993 ] score 0.5 , 1 2 4 . MRI brain scan finding reveal change indicative stroke and/or generalize cerebrovascular disease ( e.g. , ARWMC scale ) change limit : white matter lesion score 0 1 2 basal ganglion score 0 1 ) 5. caregiver willing able attend study visit perform psychometric test require presence caregiver EXCLUSION CRITERIA : ALZHEIMER DISEASE &amp; HEALTHY VOLUNEERS 1. contraindication MRI examination , e.g . metal implant phobia determine onsite radiologist perform scan 2. schedule surgery and/or another invasive procedure within time period 24 hour follow IMP application 3. allergic IMP constituent and/or history severe allergic reaction drug allergen ( e.g . patient / volunteer allergic asthma ) 4. critically ill and/or medically unstable whose clinical course observation period unpredictable , e.g . patient / volunteer within 14 day myocardial infarction stroke , unstable patient / volunteer previous surgery ( within 7 day ) , patient advance heart insufficiency ( NYHA stage IV ) , acute renal failure 5. history exposure radiation &gt; 15 mSv/year ( e.g . occupational radiation therapy ) 6. receive drug therapy treatment know lead greatly fluctuate value hematological chemical laboratory parameter severe side effect ( e.g . chemotherapy ) 7. receive antiamyloid drug therapy . 8. receive contrast material ( Xray , MRI ) radiopharmaceutical within 48 hour prior application IMP application substance plan 24 hour follow IMP administration 9. previously enrol study participate clinical study involve investigational pharmaceutical product within 30 day prior screen , and/or radiopharmaceutical within 10 radioactive halflives prior IMP administration 10. brain tumor intracranial lesion , disturbance CSF circulation ( e.g. , normal pressure hydrocephalus ) and/or history head trauma brain surgery 11. inflammatory infectious CNS disease , e.g . multiple sclerosis , HIV , syphilis , CreutzfeldJacob disease 12. history , physical , laboratory image finding indicative significant neurological psychiatric illness ( patient AD ) 13. another disease cause disturbance brain function ( e.g . vitamin B12 folic acid deficiency , disturb thyroid function ) 14. history alcohol drug abuse 15 history severe persistent depression 16.clinically significant hematologic index may put subject increase risk bleeding</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>